Humira Sales Will Get Modest Bump From Medicare Part D, Abbott Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm is seeking additional indications which could create an additional $1-$2 bil. in incremental sales beyond the TNF inhibitor’s RA base.